Friendship, Survivorship and the 3-Day

Lesleigh & Jamie at the San Diego 3-Day camping in their pink tent.

When Lesleigh H. signed up for the Susan G. Komen San Diego 3-Day® in 2009, she never expected it would lead to a lasting friendship. Looking for training partners, she reached out to fellow walkers in her area and that’s when she met Jamie R. 

“Jamie showed up. Some other people showed up, too,” Lesleigh recalled. “But Jamie and I walked the same pace, we both have long legs, we lived in the same neighborhood. We just hit it off.” 

That first training walk sparked more than just preparation for the 60-mile 3-Day. It marked the beginning of a friendship that would help carry them through some of the hardest moments of their lives. 

Lesleigh and Jamie met at a training walk in 2009 for the Susan G. Komen San Deiego 3-Day.

Lesleigh and Jamie walked together in the 2009 and 2011 San Diego 3-Days, bonding over shared stories, laughter and a mutual drive to support breast cancer awareness and research. But as life got busy, they took a break from the 3-Day, never imagining that one day they’d return, not just as walkers but as having experienced breast cancer up close and personal. 

A Shocking Diagnosis 

In 2017, Lesleigh was diagnosed with triple-negative breast cancer after discovering a painful lump in her breast. 

“It’s like the ground disappears from underneath you. It’s shocking,” Lesleigh said. “When the doctor told me it was just going to be a bump in the road and I wasn’t going to die, I cried because I was so thankful.”  

Lesleigh underwent a lumpectomy, chemotherapy and radiation therapy. In 2019, she returned to the 3-Day, this time walking with Jamie by her side, in her honor.  

Lesleigh and Jamie at the halfway point of the Susan G. Komen San Diego 3-Day.

But then, in 2022, Jamie received her own diagnosis. 

“Because of COVID, I put off my mammogram for a year,” Jamie explained. “They found a lump that was the size of a Tic Tac, so it was very small. I was very fortunate.” 

Jamie’s treatment included a lumpectomy, radiation therapy and ongoing estrogen blockers to treat her hormone receptor-positive, HER2-negative invasive ductal carcinoma.

Return to the 3-Day 

This November, Lesleigh and Jamie are returning to the San Diego 3-Day once again. This time, with even deeper meaning. 

“Lesleigh is turning 60, it’s my third year of survivorship,” Jamie said. “So, we’re walking 60 miles for her 60 years and three days for my three years.” 

Their bond has only grown stronger over time, not just through their breast cancer journeys, but through the unwavering support they’ve given each other.  

“She lifts me up. She challenges me and she shows me the way, not just the fight for cancer but for other things, too,” Lesleigh said, fighting back tears. “She’s just the best person ever.” 

More Than a Walk 

Lesleigh and Jamie walking near the beach at the Susan G. Komen San Diego 3-Day.

For both Lesleigh and Jamie, the 3-Day is about so much more than walking. 

“It’s challenging, but also so energetic and special,” Lesleigh said. “The Pink Bubble is like a bubble of joy, beauty and camaraderie. It just energizes you. The walking is hard, but the love and support around you keep you going.” 

Outside of training or walking in the 3-Day, Jamie and Lesleigh have shared other special memories together including Bunco nights, voter outreach events and birthday parties. 

“When Lesleigh and I were diagnosed, I was upset,” Jamie admitted. “But I realized this is why we’ve been doing the 3-Day all along. This is what we’ve been training for. I firmly believe that what we’ve helped raise over the years has helped us become survivors.” 

Lesleigh and Jamie crossing the finish line at the Susan G. Komen San Diego 3-Day.

To learn more about the San Diego 3-Day, visit the3day.org. 

Join us for a Susan G. Komen Mission Webinar about Triple Negative Breast Cancer

Join us next Wednesday, September 14 from 11:00 a.m. – 11:30 a.m. CT as Susan G. Komen continues our 3-Day webinar series with a new webinar focused on triple negative breast cancer. You will hear from Komen Scholar, Dr. Jennifer Pietenpol, as she unwinds the complexity of triple negative breast cancer and showcases how Komen funds have aided our understanding of triple negative breast cancer and helped pioneer novel treatment options.

This webinar will be hosted by:

  • Carrie Stovall, Director, Events
  • Michelle Martin-Pozo Ph.D., Director, Research Programs at Komen
  • Jennifer Pietenpol, Ph.D., Executive Vice President for Research at Vanderbilt University Medical Center, Director of the Vanderbilt-Ingram Cancer Center, the B.F. Byrd Jr. Professor of Molecular Oncology, and Professor of Biochemistry, Cancer Biology and Otolaryngology at Vanderbilt University School of Medicine
    • Jennifer Pietenpol, Ph.D., began her research focused on the signaling of one of the most commonly mutated genes in all of cancer: p53. More recently, Dr. Pietenpol has combined her research expertise in molecular genetics with bioinformatics to identify differences of triple negative breast cancer. Her studies have helped lead to several clinical trials aimed to help oncologists determine the most appropriate and precise treatment for breast cancer patients. Dr. Pietenpol has been recognized many times for her leadership and her work, and continues to help lead and shape cancer research nationally as demonstrated by her recent appointment to a panel advising Vice President Joe Biden’s National Cancer Moonshot.

The webinar will be 30 minutes long and you will have the opportunity to ask questions. Invite your friends, family and donors to participate and learn more about how the money you raise helps support Komen’s research.

Please send this information to your family and friends and invite them to join us, too.

WEBINAR TOPIC: Deciphering the Complexity: New Strategies for Triple-Negative Breast Cancer
DATE: Wednesday, September 14
TIME: 11:00 a.m. – 11:30 a.m. CT
REGISTER FOR THIS WEBINAR TODAY: https://attendee.gotowebinar.com/register/2966803806204000515

See you on Wednesday!

Susan G. Komen Mission Webinar: What We Learned

In June, we had the pleasure of bringing you our first ever Komen Mission Webinar. The purpose of this online meeting was to allow 3-Day participants and Komen supporters in all corners of the world to hear firsthand about the impact that Komen funds are making to one researcher’s groundbreaking work.

The webinar began with an introduction from Chrissy Mathews, Susan G. Komen 3-Day Project Manager. Chrissy welcomed Victoria Wolodzko, Vice President of Research and Community Heath Program Operations at Susan G. Komen, who shared some important information about Komen’s granting process and why it is vital for these grants to continue.

From there, it was on to the webinar’s guest of honor. Dr. Justin Balko is a researcher and professor at Vanderbilt University. With a small but brilliant team of scientists, Dr. Balko is primarily studying treatment options for triple negative breast cancer, which he succinctly defined as breast cancers that are missing certain hormone receptors; put simply, the absence of these elements means that these types of cancer often don’t respond well to many current breast cancer treatments. He described triple negative breast cancer as “a small proportion [of all breast cancers] but also the worst outcome of all of the clinically recognized subtypes. It tends to impact younger patients, it tends to have a very aggressive course, and there are really no targeted agents approved, and unfortunately because of that, it’s currently only treated with chemotherapy.” Dr. Balko went on to explain how his lab seeks to identify which patients will benefit from certain treatments, and how they can make it so that more patients respond to treatment, often involving a combination of drugs/therapies.

Up next, Dr. Balko continues with an explanation of the particular type of treatment that his lab is working on: immunotherapy. Please take a few minutes to view the next few clips from the webinar to see and hear about the truly exciting advances that are being made in this emerging field of treatment.

 

In the last few clips from the webinar, we hear Dr. Balko share what the “next steps” goals are for him and his team, and he offers his appreciation for the support that his lab gets from Komen and its supporters.

https://www.youtube.com/watch?v=DAmzfeNR5y0

https://www.youtube.com/watch?v=m_bI08ROjA8

If you’d like to view the Komen Mission Webinar in its entirety, please visit here.